Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658421 | 1.00 | PARP1 (0.49) | PARP1HTR2CHTR2BHTR2ANAMPT | |
| Hydrochloric Acid SCHEMBL3888469 | 0.98 | PARP1 (0.48) | PARP1HTR2CHTR2BHTR2ANAMPT | |
| SCHEMBL23004922 | 0.83 | OPRM1 (0.49) | PARP1 | |
| SCHEMBL30278373 | 0.83 | OPRM1 (0.49) | PARP1 | |
| SCHEMBL9280480 | 0.81 | HTR2C (0.56) | PARP1HTR2CHTR2BHTR2ANAMPT | |
| SCHEMBL1976916 | 0.77 | PARP1 (0.56) | PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL7985474 | 0.77 | HTR2C (0.50) | PARP1HTR2CHTR2BHTR2ANAMPT | |
| SCHEMBL2100919 | 0.76 | BRD4 (0.50) | PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL31184549 | 0.76 | BRD4 (0.50) | PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL31184539 | 0.76 | BRD4 (0.50) | PARP1HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022174083-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20180015085-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180009808-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-01-11 | — | — | US | disclosed |
| US-9808457-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-9802935-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170121348-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170121331-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| WO-2007130860-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130860-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130927-A2 | CONDENSED TRICYCLIC COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| EP-1809633-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060229447-A1 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-12 | — | — | US | disclosed |
| WO-2006052378-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060094707-A1 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009808-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | PARP1 1803/4885HTR2C 465/4885HTR2B 294/4885 |
| US-20060229447-A1 | Constrained compounds as CGRP-receptor antagonists | CALCR, BDKRB2, CALCRL | PARP1 876/4885HTR2C 198/4885HTR2B 181/4885 |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | CALCR, BDKRB2, CALCRL | PARP1 876/4885HTR2C 198/4885HTR2B 181/4885 |
| US-20060094707-A1 | Constrained compounds as CGRP-receptor antagonists | CALCR, BDKRB2, CALCRL | PARP1 876/4885HTR2C 198/4885HTR2B 181/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PARP1 4719/4885HTR2C 1517/4885HTR2B 2151/4885 |
| US-20180015085-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | PARP1 1981/4885HTR2C 464/4885HTR2B 271/4885 |
| US-20170121331-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | PARP1 1803/4885HTR2C 465/4885HTR2B 294/4885 |
| US-20170121348-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | PARP1 1981/4885HTR2C 464/4885HTR2B 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.